J. Haroche, F. Cohen-aubart, and B. J. Rollins, Histiocytoses: emerging neoplasia behind inflammation, Lancet Oncol, vol.18, issue.2, pp.113-125, 2017.

J. F. Emile, O. Abla, and S. Fraitag, Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages, Blood, vol.127, issue.22, pp.2672-2681, 2016.

G. Badalian-very, J. A. Vergilio, and B. A. Degar, Recurrent BRAF mutations in Langerhans cell histiocytosis, Blood, vol.116, issue.11, pp.1919-1923, 2010.

J. Haroche, C. F. Arnaud, and L. , High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other nonLangerhans cell histiocytoses, Blood, vol.120, issue.13, pp.2700-2703, 2012.

J. F. Emile, E. L. Diamond, and Z. Hélias-rodzewicz, Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease, Blood, vol.124, pp.3016-3019, 2014.

R. Chakraborty, O. A. Hampton, and X. Shen, Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis, Blood, vol.124, pp.3007-3015, 2014.

E. L. Diamond, B. H. Durham, and J. Haroche, Diverse and targetable kinase alterations drive histiocytic neoplasms, Cancer Discov, vol.6, issue.2, pp.154-165, 2016.

J. Haroche, F. Cohen-aubart, and J. F. Emile, Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease, J Clin Oncol, vol.33, issue.5, pp.411-418, 2015.

F. Cohen-aubart, J. F. Emile, and F. Carrat, Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study), Blood, vol.130, issue.11, pp.1377-1380, 2017.

A. Bhatia, G. Ulaner, and R. Rampal, Single-agent dabrafenib for BRAFV600E-mutated histiocytosis, Haematologica, vol.103, issue.4, pp.177-180, 2018.

S. Héritier, Z. Hélias-rodzewicz, and H. Lapillonne, Circulating cellfree BRAFV600E as a biomarker in children with Langerhans cell histiocytosis, Br J Haematol, vol.178, issue.3, pp.457-467, 2017.

P. Laurent-puig, D. Pekin, and C. Normand, Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy, Clin Cancer Res, vol.21, issue.5, pp.1087-1097, 2015.

E. Colomba, Z. Hélias-rodzewicz, V. Deimling, and A. , Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing, J Mol Diagn, vol.15, issue.1, pp.94-100, 2013.

Z. Hélias-rodzewicz, E. Funck-brentano, and L. Baudoux, Variations of BRAF mutant allele percentage in melanomas, BMC Cancer, vol.15, p.497, 2015.

E. L. Diamond, L. Dagna, and D. M. Hyman, Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease, Blood, vol.124, issue.4, pp.483-492, 2014.